Neith Corporation (TPEX:6236)
20.00
0.00 (0.00%)
May 21, 2026, 12:09 PM CST
Neith Revenue
Neith had revenue of 7.99M TWD in the quarter ending March 31, 2026, a decrease of -33.99%. This brings the company's revenue in the last twelve months to 32.03M, down -33.67% year-over-year. In the year 2025, Neith had annual revenue of 36.15M, down -20.68%.
Revenue (ttm)
32.03M
Revenue Growth
-33.67%
P/S Ratio
26.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
833.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.15M | -9.43M | -20.68% |
| Dec 31, 2024 | 45.57M | 5.67M | 14.20% |
| Dec 31, 2023 | 39.90M | 7.85M | 24.48% |
| Dec 31, 2022 | 32.06M | 668.00K | 2.13% |
| Dec 31, 2021 | 31.39M | -12.35M | -28.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 718.58M |
| Taiwan Advance Bio-Pharmaceutical | 364.79M |
| TCI GENE | 273.61M |
| BioLASCO Taiwan | 263.81M |
| GeneReach Biotechnology | 232.55M |
| Lukas Biomedical | 179.49M |
| NatureWise Biotech & Medicals | 176.77M |
| Holy Stone Healthcare | 47.51M |